---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-107249"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:59:21.775907+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma completes second dose cohort in EB103 trial; 100% CR rate

## Summary
- 100% complete response (CR) rate at Month 1 in all evaluable patients in second dose cohort of STARLIGHT-1 trial.
- All patients are high-risk, including one with CNS lymphoma; no treatment-related serious adverse events reported.
- DSMB will review cumulative data to determine Recommended Phase II Dose (RP2D) for expansion phase.
- EB103 is a CD19-redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell Non-Hodgkin's Lymphoma (NHL).

## SEC filing metadata
- accession: 0001213900-25-107249
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390025107249/0001213900-25-107249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390025107249/ea0264099-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-107249
- JSON: https://secwatch.observer/filing/0001213900-25-107249.json
- Plain text: https://secwatch.observer/filing/0001213900-25-107249.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.